Skip to main content
Scope Fluidics S.A. logo

Scope Fluidics S.A. — Investor Relations & Filings

Ticker · SCP ISIN · PLSCPFL00018 LEI · 259400EUNFX4E2BEHU15 WAR Professional, scientific and technical activities
Open in API
Filings indexed 510 across all filing types
Latest filing 2020-05-21 Regulatory Filings
Country PL Poland
Listing WAR SCP

About Scope Fluidics S.A.

https://scopefluidics.com/

Scope Fluidics S.A. is a biotechnology company that develops innovative medical diagnostic solutions based on microfluidic technologies. The company's business model involves incubating projects within special-purpose vehicles (SPVs) with the goal of selling them to global strategic partners. Its primary project, developed by its subsidiary Bacteromic Sp. z o.o., is the BACTEROMIC system. This automated system provides rapid, comprehensive antimicrobial susceptibility testing (AST) to address the challenge of antibiotic resistance. Previously, the company developed the PCR|ONE system for rapid molecular diagnostics through its Curiosity Diagnostics SPV, which was acquired by Bio-Rad in 2022. The company focuses on creating fast, effective, and accessible diagnostic tools to improve healthcare outcomes.

Recent filings

Filing Released Lang Actions
Rekomendacja projektu rozwijanego przez Scope Fluidics, w ramach konkursu Covid-19 prowadzonego przez Agencję Badań Medycznych - Content (PL)
Regulatory Filings Classification · 1% confidence The document text is a short announcement (809 characters) from the Management Board ('Zarząd') of Scope Fluidics S.A. It details receiving a conditional recommendation for funding (approx. 2.6 million PLN) from the Medical Research Agency ('Agencja Badań Medycznych') for a project by its subsidiary. This concerns potential financing/grant acquisition, which falls under Capital/Financing Update (CAP). It is not a full report, earnings release, or a standard regulatory filing like 10-K or IR. Given the subject matter is securing funding/grants, CAP is the most appropriate specific category.
2020-05-21 Polish
Osiągniecie etapu „proof-of-concept” w rozwoju panelu umożliwiającego przeprowadzenie testu na obecność wirusa SARS-CoV-2 z wykorzystaniem systemu PCR|ONE - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a formal announcement from a company (Scope Fluidics) referencing a previous report and detailing a significant technical milestone ('proof-of-concept') achieved in the development of a SARS-CoV-2 diagnostic test using their PCR|ONE system. It outlines the technical steps completed and the future development plan (testing, registration, etc.). This type of update, focusing on operational progress, strategic development, and future plans, is characteristic of a general regulatory announcement or a significant business update that doesn't fit neatly into specific financial reports (10-K, IR, ER) or governance documents. Since it is a specific, material operational update that is not a standard financial report, and it is not explicitly announcing the publication of another report (RPA), the most appropriate general category for significant, non-standard regulatory disclosures is 'Regulatory Filings' (RNS). The length (under 5,000 characters) suggests it is a concise announcement rather than a full report.
2020-05-15 Polish
Zakończenie piątego etapu prac nad projektem BacterOMIC - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a formal announcement from the Management Board (Zarząd) of Scope Fluidics S.A. written in Polish. It details the successful completion of the fifth research and development (R&D) milestone for the BacterOMIC system, specifically achieving readiness for pre-registration testing. The text describes technical achievements, such as producing new analyzer and cartridge-filling device versions, adapting software, creating test cartridges, and optimizing the design. It also mentions the plan for subsequent pre-validation testing and potential risks related to COVID-19. This content focuses on the progress of a specific project, which aligns best with an update on company activities or a specific project milestone report, rather than a standard financial filing like 10-K, ER, or IR. Since there is no specific category for R&D progress reports, and it is a detailed update on operational/project status, it is most closely related to general corporate information. Given the options, it is not a standard financial report, management discussion, or governance document. It is a specific operational update. In the absence of a dedicated R&D/Project Update code, and considering it is a detailed report on internal progress rather than a brief announcement of a report (RPA/RNS), it falls under a general corporate disclosure. However, none of the codes perfectly fit a detailed R&D milestone report. If we must choose the closest fit among the provided codes, it describes significant internal development and operational progress. Since it is a detailed report on internal progress, it is not a simple 'Regulatory Filing' (RNS) or 'Report Publication Announcement' (RPA). It is a substantive update on the company's core activities. Given the options, and recognizing this is a detailed operational/project update, it is often grouped with Management Reports (MDA) or sometimes treated as a general Regulatory Filing (RNS) if it's a mandatory disclosure in its jurisdiction. Since it details operational progress and outlook related to a product, MDA is a possibility, but MDA usually refers to the Management Discussion & Analysis section of a formal financial report. As this is a standalone, detailed update on a specific project's progress, and it doesn't fit the other specific financial/governance/shareholder codes, the most appropriate fallback for a substantive, non-standard disclosure is RNS (Regulatory Filings/Miscellaneous). However, if we interpret 'Management Reports' (MDA) broadly as detailed management commentary on business trends (even project trends), it could fit. Given the highly technical and project-specific nature, and lack of financial figures, RNS is the safest general classification for a non-standard disclosure.
2020-04-09 Polish
Zakończenie piątego etapu prac badawczo-rozwojowych nad systemem PCRIONE - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a 'raport bieżący' (current report) issued by Scope Fluidics, which is a standard regulatory filing format in Poland for public companies to disclose material information. It details the progress of R&D milestones (PCR|ONE system), clinical validation steps, and operational updates. It does not constitute a full financial report (10-K/IR), nor is it a simple announcement of a report (RPA). It falls under the category of general regulatory announcements and corporate disclosures. Q2 2020
2020-04-07 Polish
Powiadomienie o nabyciu warrantów subskrypcyjnych oraz powiadomienie o nabyciu akcji
Director's Dealing Classification · 1% confidence The document text is titled "Powiadomienie o transakcji/transakcjach, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of transaction(s) referred to in Article 19(1) of the MAR Regulation). This regulation mandates disclosures regarding transactions conducted by persons discharging managerial responsibilities (PDMRs). The content details transactions (Nabycie/Subskrypcja - Acquisition/Subscription) involving shares by a Member of the Management Board ('Członek Zarządu'). This directly corresponds to the definition of Director's Dealing (insider trades by executives). Therefore, the appropriate code is DIRS.
2020-03-25 Polish
Otrzymanie zawiadomień, o których mowa w art. 19 ust. 1 MAR - Content (PL)
Director's Dealing Classification · 1% confidence The document text is very short (653 characters) and explicitly states that it is reporting transactions made by a person discharging managerial responsibilities (PDMR) concerning the acquisition of warrants and shares, referencing Article 19 of the MAR Regulation. It concludes by stating that the notifications ('Otrzymane zawiadomienia') are attached to the report. This structure—a brief announcement referencing attached insider transaction notifications—strongly suggests a filing related to insider dealings. The specific category for director/executive share transactions is 'Director's Dealing' (DIRS). Although it is a brief announcement, the content is specific enough to classify it as DIRS rather than the general fallback RNS, as it details the nature of the transaction (warrants/shares acquisition by an executive).
2020-03-25 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.